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Abstract Chikungunya fever is a tropical vector-borne disease that has been spreading rapidly
around the world during the last 10 years, and which has been usually misdiagnosed as dengue.
Nowadays, this disease is increasing in Mexico, mainly in the southern and central zones of
the country, being signiﬁcantly more common in women, children and young adults (28% in < 20
years of age). The classical presentation includes fever, arthralgia, polyarthritis, back-pain, and
skin rashes. Although symptoms and treatment are similar to those for dengue, there are key
clinical features to differentiate these two diseases.
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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Enfermedad por virus de chikungunya: actualidad en México
Resumen La enfermedad por el virus chikungunya es una enfermedad tropical transmitida por
vector, que en los últimos 10 an˜os ha tenido una gran diseminación mundial y ha sido históri-
camente subdiagnosticada debido a las características en común con el dengue. Actualmente
la incidencia en México ha ido en aumento, sobre todo en el centro-sur del país. Es más común
en mujeres, adultos jóvenes y nin˜os (28% son menores de 20 an˜os). El cuadro clínico suele pre-
sentarse con ﬁebre, artralgia, poliartritis, dolor de espalda, cefalea y erupciones cutáneas. A
www.elsevier.es/bmhim
Boletín Médico del
Hospital Infantil de México (English Edition)
ww .els vi r.es/bmhim
Boletín Médico del
Hospital Infantil de México (English Edit on)pesar de que el tratamiento es sintomático y similar al del dengue, existen datos clínicos clave
para diferenciarlas.
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. Introduction
he term ‘‘chikungunya’’ is derived from the word kungun-
ala, from the African kimakonde language, which means
‘one who slouches’’ in reference to the stooped posture
dopted by the people because of the unbearable joint and
uscular pain1.
It is an arboviral infection caused by the chikungunya
irus (CHIKV), which is transmitted by the bite of infected
edes mosquitoes. The main clinical manifestations are
ever, arthralgia, polyarthritis, backache, headache, and
kin rash2. The treatment is symptomatic, with the appli-
ation of analgesics.
. History
he ﬁrst CHIKV outbreak was reported in July, 1952, in
n epidemic that occurred over the plateaus of Mawia,
akonde and Rondo, now Tanzania. However, retrospective
tudies suggest that the epidemic of CHIKV has occurred
n Africa for centuries, with outbreaks exported to Asia
nd America in the 18th and 19th centuries although those
utbreaks were documented as dengue. Some terms such
s genoux, dengue, knokkelkoorts (knuckles fever), by the
nhabitants of Batavia, aburokab (fever of the knees) by the
reeks, and 3-day fever in Calcutta, have been given to this
pidemic1,3.
Testimony of this is the classic report widely cited as the
rst description of the dengue epidemic by David Bylon, a
urgeon in the city of Batavia (Jakarta), who contracted the
isease and wrote the following in 1779:
‘‘It was on May 25, at 5:00 in the afternoon when I noted
that while I chatted with two good friends of mine, an
increased pain in my right hand and forearm joint was
step by step proceeding way up toward the shoulder and
then continued towards all my limbs; and by 9:00 of the
same afternoon I was already in bed with high fever...
There have been 3 weeks since... I was hit by the disease,
and because of that I had to stay home for 5 days; but
even until today, I have a continuous pain and stiffness
in joints of both feet with discomfort in both ankles, so
much that when I wake up in the mornings, or sit for a
while and start to move again, I cannot do it very well,
and going up and down stairs is very painful’’4.
This report of febrile illness of sudden onset with joints
nvolved suggests that the disease was CHIKV. That same
ear in Cairo and Alexandria (Egypt) another outbreak of
he disease took place with a strong resemblance to CHIKV,
n which attack rates reached 40-50%. The soil of these
lateau is highly permeable, so local residents need to store
ater. This results in large populations of Aedes (Stegomyia)
egypti, generally considered to be the domesticated form
f A. aegypti which efﬁciently transmit arboviruses, such as
ellow fever and dengue.
The virus became endemic in Africa by outbreaks that
ccurred in Uganda, Democratic Republic of the Congo,
imbabwe, Senegal, Nigeria, South Africa and Kenya. Par-
icularly in Uganda, it was found that the arboreal mosquito
edes africanus becomes infected naturally, being the ﬁrst
vidence of the jungle CHIKV enzootic cycle3.
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After the outbreak of 1952, the virus was spread to India
nd countries in Southeast Asia, a leader in epidemics during
he following years. The ﬁrst evidence of CHIKV outside of
frica came from Bangkok, Thailand, where the virus was
solated in 1958 during the outbreak, and associated with the
ransmission of A. aegypti, followed by several outbreaks
n Cambodia, Vietnam, Malaysia and Taiwan. On the other
and, the ﬁrst epidemic reported in India was in Kolkata
formerly Calcutta), West of Bengal, in 19631,3.
In 1964, antibodies were detected in non-human pri-
ates (NHPs) captured in the current Zimbabwe, and green
onkeys were shown to be hosts able to amplify the
ransmission of CHIKV using mosquitoes. Since then, sev-
ral studies have conﬁrmed the role of the NHPs and A.
fricanus, A. furcifer and other arboreal mosquitoes as
nzootic vectors1.
.1. Recent outbreaks
n 2004, a new outbreak emerged, which started at the coast
f Kenya (Mombasa); in the next two years it spread to
ertain islands in the Indian Ocean, such as The Reunion,
omoros, Mayotte, Madagascar, Mauritius, Seychelles and
aldives. It is estimated that 500,000 cases occurred since
he spring of 2004 until the summer of the 20065,6.
The epidemic spread from the islands of the Indian Ocean
o India, where major outbreaks occurred in 2006. Once
ntroduced, CHIKV spread to 17 of the 28 states of India,
nfecting more than 1.39 million people before the end
f the year. The outbreak in India continued until 2010, with
he emergence of new cases in non-affected areas during the
nitial phase of the epidemic. Outbreaks also spread from
ndia to the Andaman and Nicobar Islands, Sri Lanka, the Mal-
ives, Singapore, Malaysia and Indonesia through travelers
ho were in the viremic phase5.
Concern over the spread of CHIKV peaked in 2007,
hen it was detected that the virus was spreading in an
utochthonous form (human-mosquito-human) in the North
f Italy, after being introduced by a viremic traveler retur-
ing from India. The Italian Ministry of Health conﬁrmed 160
ases in Rabean of which an 83-year-old man died. A year
ater, the ﬁrst imported case was detected in Canada5,6.
In 2010, two cases not imported were detected in the
ar region, in southeast France; other cases were imported
n Australia, United States and Taiwan, while in October,
en cases were reported in southern China in the city of
ongguan. At the end of that year, a case was diagnosed in
a Rioja (Spain) in a person who had visited the North of
ndia shortly before. Subsequently, in September of 2013, a
ase was detected at the coast of Valencia in a surfer who
ad spent the summer in the Senegal coast5.
In 2013, the Panamerican Health Organization (PAHO)
eported the ﬁrst autochthonous cases in America, speci-
cally on the island of St. Martin, in the Caribbean. In May
014, it reported local circulation of the disease in several
slands of the Caribbean such as Antigua and Barbuda, Haiti,
ominican Republic and St. Kitts, among others7. That same
ear the ﬁrst case in Mexico occurred in a 39-year-old woman
ho traveled to the Caribbean on May 21st passing through
he islands of St. Thomas, St. Martin and St. Kitts, to reach
ntigua and Barbuda, where she remained until May 28th5,8.
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4Figure 1 Number of chikungunya fever cases by group of a
Studies on CHIK virus in different geographical areas show
the prevalence of three lineages with genotypic and anti-
genic distinctions. In Africa, two genotypes were attributed
to epidemics and they kept the name of the region where
they appeared, West Africa (WA) and the Eastern Central
Region of South Africa (ECSA); and the Asian genotype was
represented throughout Asia. However, the 2005-2006 epi-
demics included the introduction of the ECSA genotype to
the Asian continent for the ﬁrst time5.
3. Epidemiology
Currently, CHIKV disease has had a wide distribution in
tropical and subtropical countries around the world, high-
lighting the Asian and African continents, the Western
Paciﬁc, the Caribbean, South America and, more recently,
North America1.
In Mexico, epidemiological surveillance started formally
until 2014. However, in the data reported, a distinction
between suspected and conﬁrmed cases has been not made.
In that year, data revealed that all groups of age were
exposed to CHIKV. The most affected group was that of 25 to
44 years of age, with a 34.8%. Nevertheless, the population
< 19 years of age represented 28% of the total population,
which highlights the importance of the disease in pediatric
population (Figure 1)9.
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Figure 2 Mexican states with the highest frequency of chikunguny
12 (Source: DGEPI/Boletín epidemiológico semanal: week 49 of 2015Mexico, 2014 (Source: DGEPI/Anuarios de morbilidad 2014).
In 2015, there was a signiﬁcant increase in reported
ases, with a total of 11,394 cases (accumulated until
ecember 12), compared to 222 cases in 2014. In terms of
eographical location (Figure 2), mostly affected states are
n the South of the country, which coincides with the trend
f the vectors to settle in warm and humid zones10. Proba-
ly, low educational level in some of these states conditions
minor spreading and practice of preventive measures.
Women have been notably more affected than men,
hich may be explained with the cultural custom of women
o work at home, where the main vector (A. aegypti) of
HIKV sets, usually associated with deposits of water. In
exico, in 2015 (up to 12/12/15), the number of cases
eported by gender were 7,285 female (65%) and 3,915 male
35%)4,10,11.
In 2015, the highest transmission of CHIKV occurred dur-
ng the summer and then decreased over the course of
utumn, unlike dengue which increased to its highest preva-
ence in November (Figure 3)10.
. Etiologyhe CHIKV belongs to the genus Alphavirus, which belongs to
he family Togaviridae. It is a small size (65-70 nm diameter)
ingle-stranded RNA of positive sense virus, with a symmet-
ical icosahedral capsid, enveloped by 80 peaks with trimers
ChiapasColimaYucatánxaca
ates
a fever cases reported during 2015, accumulated to December
).
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pigure 3 Monthly comparison of reported cases of dengue and
eekly epidemiological bulletins available in 2015).
f E1 and E2 glycoproteins in each one of them. E2 glyco-
rotein complexes join to unknown cell receptors and then
nter the cell by endocytosis. The E1 glycoprotein includes
fusion peptide which promotes the release of nucleocap-
ides in the cytoplasm of host cell when it is exposed to low
H in endosomes1.
. Mutations
mutation was detected in 90% of the viruses isolated from
he CHIKV outbreak on the island of Reunion, France, which
egan in March 2005 and ended in April 2006 registering
44,000 cases (123 severe cases, 41 cases of mother to
hild transmission, and 203 associated deaths). The muta-
ion occurs at the level of residue 226 of the E1 glycoprotein
f the fusion membrane (E1-A226 V). It is postulated that this
ould facilitate the replication and transmission of the virus
y reducing its dependence on cholesterol1.
. Vectors
. aegypti and A. albopictus are invasive species that inhabit
ropical and temperate regions. Their ability to breed in
rtiﬁcial containers facilitates their passive spread through
he main routes of transport. A. aegypti has domestic and
eridomestic habits. Usually, it does not occupy territories
ocated more than 1,000 m above the sea level, although
t has occasionally been found up to 2,400 m. In contrast,
. albopictus has jungle habits and proliferates in wild envi-
onments, and it is responsible for the transmission of the
irus in rural or semi-urban areas; this is due to the adaptive
utations of the viral genome, which increase its replication
n this vector. Aedes eggs resist desiccation and extreme
emperatures, staying viable from 7 months to a year,
hich signiﬁcantly hinders the eradication of the vector. In
merica, many regions are susceptible to invasion and
pread of this virus, and the recent emergence of urban
pidemics of dengue fever in South America highlights the
otential danger of chikungunya fever12,13.
The main vectors of the CHIKV in Asia and Indian Ocean
re also Aedes aegypti and Aedes albopictus, but other
b
s
iungunya fever during 2015 (Source: approximate data with the
pecies of Aedes (A. furcifer, A. vittatus, A. fulgens, among
thers) can also transmit the infection12.
. Transmission
he transmission cycle requires infection of female
osquitoes through the blood of infected people. After an
dequate extrinsic incubation period (at least 48 h), it is
ransmitted to another host through the bite of infected
emale mosquitoes. The hosts remain viremic approximately
ntil fever has gone10,12.
During outbreak periods, humans are the main reser-
oir of the virus, which remains in circulation between
osquitoes and humans while, in interepidemic periods,
arious vertebrates have been implicated as reservoirs
non-humans primates, rodents, birds and small mam-
als). Vertical viral transmission and through breastfeeding
as been documented; furthermore, when infection occurs
uring delivery or shortly before, the transmission rate
ncreases to levels close to 50%. There is a possibi-
ity of transmission through transfusion of blood or blood
roducts13.
. Pathophysiology
he virus anchors to the cells with its E2 glycoprotein,
enerating its endocytosis; later, its RNA acts as mRNA to
ynthesize four non-structural proteins, which will inﬂuence
he production of other proteins required for replication14.
rohibitine has been identiﬁed as a receptor for the virus15.
HIKV evades the immune system by means of the pro-
ein nsP2, which hydrolyzes RNA polymerase, inhibiting the
ranscription of some genes involved in antiviral response.
acrophages and sinusoidal endothelium of the liver have
een identiﬁed as cellular reservoirs, and joints, muscle,
ermis tissue and ﬁbroblasts are targets to the virus. The
resence of inﬂammatory inﬁltrate with viral replication has
een documented in skeletal muscle and, in some cases, in
ynovial ﬂuid12,16,17.
Inﬂammation of joints is mainly caused by adaptive
mmune response. IgM antibodies are present as early as
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2 days after the onset of symptoms, and persist for weeks
to months, while IgG is usually detected when the virus is
eliminated, and persist for many years, which prevents the
reinfection of virus13,18. The antibody response is mainly of
the IgG3 isotype (neutralizing) and it is associated with the
elimination of the virus13, although the persistence of anti-
CHIKV IgM in serum, and of the virus in tissues of joints and
in the endothelial reticulum system may explain the chronic
arthropathy 12,14,16,19.
In the acute phase, the infection triggers the release of 
various cytokines, such as IL-6, G-CSF, GM-CSF, MCP1, TNF- 
, CXCL9, CCL2 and CXCL10, persisting only IL-17, IL-6, and 
GM-CSF, the latter two associated with arthralgia. There 
is also an increase in IL-18 induced by the Th1 response. 
This interleukin has a negative feedback because it induces 
the production of INF, which in turn induces the increase 
in the IL-18 binding protein (IL-18BP), a natural regula-
tor of IL-1820. With respect to NK cells, these overexpress
the CD94/NKG2C receptor, although the mechanism
through which it interferes with the infection is still un-
known5. It has been shown that the increase in IL-1 and
IL-6 is related with a poor outcome.
The virus may spread to the CNS, showing tropism
towards choroid plexuses, CSF, ependymal cells and
meninges12,19. Regarding pregnancy, it has not been found in
placental tissue. Increasing age is a risk factor for develop-
ing serious illness; however, in children, newborn are more
susceptible12,13,16.
9. Clinical features
After intradermal inoculation of the virus by the mosquito,
72 to 97% of the patients develop the symptoms after an
incubation period that can vary from 1 to 12 days (on average
lasts from 2 to 4 days)13,16. Initially, the disease is character-
ized by a sudden onset of high fever with myalgia and severe
arthralgia which may even interfere with sleep. Headache,
photophobia, rash, weakness, fainting, confusion or deﬁcit
attention disorders can occur16,19.
Fever starts suddenly and usually exceeds 39 ◦C, remains
constant for 2-7 days until it suddenly stops13. Less than 33%
of the patients have a second febrile peak21.
Joint affection is present in 70 to 100% of the patients,
and it is characterized by severe arthralgia with subacute
to chronic arthritis, joint effusion, stiffness and, in some
cases, tenosynovitis may appear13,21. The condition tends
to be symmetrical, mainly in the interphalangeal joints of
hands and feet, metacarpal, metatarsophalangeal, ankles,
wrists and knees12,13,16. The joint signs and symptoms are
usually resolved within 1-2 weeks; however, in 12-57% of
the patients, arthralgias persist in the same places for more
than 3 months up to years, ﬂuctuating in intensity and dura-
tion. People over 45 years with more severe pain initially,
and especially those who have pre-existing osteoarthritis,
are the most susceptible patients to chronic affection by
CHIKV13,17.
Since the onset of fever until 5 days later, 50% of
the patients develop vesicular or bullous dermatosis with
desquamation, or maculopapular and petechial exanthema
which is sometimes itchy and disappears with pressure (more
often in adults); it affects the trunk, and can extend to
a
c
e71
alms, soles and face. It tends to be ﬂeeting but it may
ersist over 2 days13,21,22. Hyperemia of the outer ear, which
eﬂects chondral inﬂammation possibly related to infection
y CHIKV, is also observed19.
Fifty percent of pediatric patients has 1 or 2 of the fol-
owing symptoms: convulsions, loss of stool consistency or
eripheral cyanosis21,22. Neurologic complications are fre-
uent causes of hospitalization in these patients with CHIKV
nfection, and these are mainly febrile convulsions, viral
ncephalitis and acute encephalopathy19.
In a study conducted in pregnant women, in La Reunion,
rance, CHIKV infection was not associated with an
ncreased frequency of abortions, but intrapartum verti-
al transmission or congenital malformations have been
bserved. In the ﬁrst case, after the incubation period, the
hild has fever (79%), rash (82%), and peripheral edema
58%); regarding congenital malformations, a slight increase
n the closure defects of the neural tube, chromosomal
bnormalities, soft palate and cardiac defects (42%) were
bserved in children of women who were infected by CHIKV
uring pregnancy, although these data had no statistical
igniﬁcance to establish a causal relationship4,22. Cardiac
efects include myocardial hypertrophy, ventricular dys-
unction, pericarditis and dilation of the coronary arteries22.
Among the rare manifestations of CHIKV infection
re hemorrhaging, such as conjunctival injection and bleed-
ng of the higher or lower digestive tract, not necessarily 
elated to the degree of thrombocytopenia. Also, myocardi-
is, Guillain-Barré Syndrome, Raynaud’s disease, loss of 
uditory acuity (related to the chondritis), uveitis or infec-
ious retinitis have been observed13,18.
0. Conﬁrmatory diagnosis
he gold standard for conﬁrmation of chikungunya fever
s real time polymerase chain reaction (RT-PCR) directed
oward the gene of the non-structural protein of CHIKV
NSP1) or the gene of the viral envelope of CHIKV (E), either
n blood or synovial ﬂuid21.
Other methods to conﬁrm the diagnosis are the detection
f response to antibodies with ELISA, indirect immunoﬂuo-
escence, or reverse transcription loop-mediated isothermal
mpliﬁcation (RT-LAMP)8. However, although the anti-CHIKV
gM appears after 2-3 days since onset of symptoms, titers do
ot reach detectable concentrations by ELISA until the ﬁrst
r second week, and may be present until a year later5,23.
Speciﬁc IgG for CHIKV rises 10-13 days after the onset
f symptoms and persists with high titers for years, pre-
ominantly in the form of IgG31. The persistence of high
iters of immunoglobulins and its correlation with chronic
isease suggest an impaired antigenic depuration in these
atients22.
Hematic cytometry often shows leukopenia and
ometimes very mild thrombocytopenia (100,000
latelets/mm3). Unlike other viral diseases, markers
f inﬂammation, such as the sedimentation rate of erythro-
ytes and C-reactive protein, tend to be high, and there is
lso an increase in hepatic transaminases.
Joint radiographs show no alterations except in the
hronic condition after 1 year, in which there are signs of
rosive arthritis and reduction of the articular space8.
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Table  1  Clinical  comparison  between  fever  by  dengue  and
by  chikungunya.
Clinical  features  Chikungunya  fever  Dengue
Fever  +++  ++
Myalgia +  ++
Arthralgia +++  +/-
Rashes ++  +
Blood dyscrasia  +/-  ++
Shock -  +/-
Leukopenia ++  +++
Lymphocytopenia +++  ++
Neutropenia +  +++
Thrombocytopenia +  +++
Average frequency of symptoms from studies where both
diseases were compared; + + + = 70-100% of patients; + + = 40-
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Adapted from OPS/OMS. Preparation and response against
Chikungunya virus in the Americas, 2010 (reference 15).
Since  there  are  often  difﬁculties  to  perform  the  con-
rmatory diagnosis  of  this  disease,  the  PAHO  suggests  the
ollowing deﬁnitions24:
Suspected  case:  patient  with  fever  >  38 ◦C  (101 ◦F)  and
evere arthralgia  or  arthritis  of  acute  onset  not  explained
y other  medical  conditions,  and  that  endemic  or  epidemic
reas have  been  affected  during  the  two  weeks  prior  to  the
nset of  symptoms.
Conﬁrmed case:  suspected  case  with  a  positive  speciﬁc
est for  CHIKV  (viral  isolation,  RT-PCR,  IgM,  or  a  four-fold
ncrease in  titers  of  antibodies  for  chikungunya).
1. Differential diagnosis
engue  is  the  most  alike  and  most  often  confused  disease
ith chikungunya  fever,  partly  because  they  share  the  same
ector (A.  aegypti)  and,  therefore,  its  same  geographic
pace. The  most  important  clinical  data  to  differentiate
t with  dengue  is  the  severe  polyarthralgia,  which  is  much
ore frequent  in  chikungunya  fever;  however,  it  should  also
e considered  that  it  shows  a  more  abrupt  start,  and  a  higher
ut of  less  duration  fever  than  dengue.  Rashes,  conjunctival
njections and  arthralgias  are  more  frequent  in  chikungunya
ever than  in  dengue  (Table  1)16.
Other  laboratory  data  for  the  differential  diagnosis  are
ormocytic normochromic  anemia,  hemoconcentration  and
hrombocytopenia and  neutropenia,  which  are  usually  found
n dengue  and  not  in  chikungunya  fever,  in  which  lymphope-
ia is  more  common16.
Zika  virus  infection  is  a  new  Aedes  transmitted  disease
hat is  spreading  aggressively  in  Africa,  South  and  Cen-
ral America.  Its  clinical  features  are  similar  to  those  of
hikungunya fever  and  dengue;  but  maculopapular  rash,
on-purulent conjunctivitis  are  seen  more  often  in  Zika
irus infection.  Of  these  three  entities,  Zika  virus  infec-
ion has  the  higher  rate  of  neurological  and  teratogenic
omplications, particularly  Guillain-Barre  syndrome  and
icrocephalus, respectively.  It  is  very  important  to  make
 conﬁrmatory  diagnosis  by  RT-PCR25--27.
Leptospirosis should  be  discarded  in  patients  with  a  his-
ory of  contact  with  water,  mud,  or  rodents  in  an  endemic
1
C
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rea.  In  this  disease,  it  is  common  to  ﬁnd  serious  myal-
ia in  gastrocnemius  muscles,  with  or  without  oliguria
nd jaundice,  neutrophilia  and  elevated  titers  of  creatine
hosphokinase13.
To  clinically  rule  out  malaria,  the  febrile  pattern  should
e observed,  which  tends  to  be  periodic  in  this  pathology.
heumatic fever  should  also  be  considered  if  the  disease
resents an  asymmetric  and  migratory  polyarthritis  that
nvolves mainly  the  large  joints,  and  complies  with  the  Jones
riteria4.
In some  parts  of  the  world  there  are  other  endemic
rthritogenic alpha  viroses.  The  Mayaro  fever  is  typical  of
orest areas  and  has  a  very  similar  presentation  than  chikun-
unya fever,  although  it  shows  a  little  less  frequency  in
oint involvement  (50-90%);  it  also  has  peripheral  edema
58%), retroorbital  headache  (40-60%),  dizziness  (25%),  sore
hroat (18%),  lymphadenopathy  (17%),  vomiting  (4-14%),
iarrhea (9%),  and  gingivorragia  (5%)20.  Other  types  of
ever by  alphavirus  with  very  similar  symptoms  are  caused
y the  Ross  River  virus  and  the  Barmah  Forest  virus  in
ustralia and  some  Paciﬁc  Islands,  the  Onyong-nyongvirus
n Africa,  and  the  Pogostavirus  in  Finland,  among  others.
herefore, it  should  be  considered  if  there  is  a  history  of  a
ecent trip  to  or  of  origin  from  any  of  these  sites,  although
reatment does  not  vary  much16.
2. Treatment
here  is  still  no  speciﬁc  or  effective  antiviral  treatment
hich reduces  the  therapeutic  measures  to  physical  me-
hods, and  the  administration  of  acetaminophen  (symp-
omatic treatment)  for  treating  fever3,7.  If  acetaminophen
oes not  work,  NSAIDs  or  narcotics  can  be  used28.  Research
s currently  carried  out  on  treatments  with  CHIKV  antibod-
es, IFN-,  chloroquine  and  rivabirin;  the  latter  has  been
sed in  some  severe  forms  but  its  effectiveness  has  not  been
onﬁrmed8,12,15.  Chloroquine  could  interfere  with  the  entry
f the  virus  to  cells,  while  rivabirin  is  an  inhibitor  of  viral
eplication28.
There  are  other  drugs,  but  their  effectiveness  is  still
ot evaluated  in  humans.  The  use  of  inhibitors  of  CCL2
as reduced  the  inﬂammatory  inﬁltrate  in  muscle  and
oints in  mice  infected  with  CHIKV19.  For  chronic  rheumatic
anifestations and  polyarthritis  that  last  more  than  2-3
onths, the  use  of  antirheumatics  such  as  methrotrexate
s recommended12.
3. Prognosis
hikungunya  fever  has  a  very  low  mortality  rate  (1  in  1,000);
owever, the  recovery  can  be  prolonged  and  arthralgia
ay persist  for  months  or  even  years12,19. Pediatric  and
lderly patients  are  the  groups  with  most  risk  of  dying
ecause CHIKV,  being  the  main  causes  of  death  hepatitis
nd encephalitis  in  childhood,  and  heart  failure  and  multiple
rgan failure  in  the  eldery16,17.4. Prevention
hikungunya  fever  prevention  measures  are  based  on  avoid-
ng mosquito  stings,  killing  the  mosquitoes  and  avoiding  the
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formation of A. aegypti breeding places; just as for other
diseases transmitted by these vectors5.
The evasion of mosquito bites can be done in different 
ways, using topic repellents such as n-diethyl-m-toluamide 
(DEET), which in children is recommended in concentrations 
below 30% and should be applied directly on the exposed skin 
avoiding contact with mucous membranes; or environmental
repellents (insecticides, such as permethrin), so long slee-
ves that can be sprayed with (resists 4-5 washes); avoiding
the use of perfumes that attract mosquitoes; installation of
air conditioning, mosquito nets in windows and beds13.
The elimination of the vector can be done with insec-
ticides or physical, or biological methods; however, at
endemic areas, it is easier to avoid the accumulation of
water and waste, periodically emptying containers that
accumulate water in yards. If accumulation cannot be
avoided, a light oil ﬁlm can prevent the deposit of eggs, or
a larvicide such as temephos can be used. There are some
studies in cities of Vietnam where they promoted the pro-
liferation of Copepods, a group of small crustaceans that
eat mosquitoes, and they obtained positive results in the
regulation of mosquitoes in the urban zone, and in dengue
incidence29.
There have been some attempts to develop chikungunya
vaccines. The US Navy has developed a promising attenuated
vaccine that appeared to be safe and effective, but research
has been discontinued because the military interests of this
institution have been modiﬁed. Inactivated vaccines with
good protective response for CHIKV, such as the detergent-
inactivated vaccine and the formalin-inactivated vaccine,
have also been developed but there is still not enough
support of clinical research. Recently, a chikungunya virus-
like particle vaccine and a recombinant measles-virus-based
chikungunya one have been tried, each one in a short phase
I trial (25 and 26 patients, respectively), in which both
showed the induction of chikungunya virus neutralizing anti-
bodies in 100% of the patients. Further investigation on
these potential chikungunya vaccines is needed. Aside from
preventing the long-lasting effects of the disease, a chikun-
gunya virus vaccine will reduce the economic and social
impact that the disease has in endemic countries due to
health care costs, loss of working days and impairment in
tourism, which is a very important source of income in a lot
of countries17,30.
Conﬂict of interest
The authors declare no conﬂict of interest of any nature.
References
1. Burt FJ, Micheal S, Rolph MS, Rulli E, Mahalingam S, Heise MT.
Chikungunya: a re-emerging virus. Lancet. 2012;379:662--71.
2. Petitdemange C, Wauquier N, Vieillard V. Control of
immunopathology during chikungunya virus infection. J
Allergy Clin Immunol. 2015;135:846--55.
3. Kaur P, Hann-Chu JJ. Chikungunya virus: an update on
antiviral development and challenges. Drug Discov Today.
2013;18:969--83.
4. Cherry J, Demmler-Harrison GJ, Kaplan SL, Steinbach WJ, Hotez
P. Feigin and Cherry’s textbook of pediatric infectious diseases.
Philadelphia: Elsevier-Saunders; 2013.
273
5. Hwu JR, Kapoor M, Tsay SC, Lin CC, Hwang KC, Horng JC, et al.
Benzouracil-coumari-arene conjugates as inhibiting agents for
chikungunya virus. Antiviral Res. 2015;118:103--9.
6. Pierro A, Rossini G, Gaibani P, Finarelli AC, Moro ML, Landini MP,
et al. Persistence of anti-chikungunya virus-speciﬁc antibodies
in a cohort of patients followed from the acute phase of infec-
tion after the 2007 outbreak in Italy. New Microbes New Infect.
2015;7:23--5.
7. Thiberville SD, Moyen N, Dupuis-Maguiraga L. Chikungunya
fever: epidemiology, clinical syndrome, pathogenesis and ther-
apy. Antiviral Res. 2013;99:345--70.
8. Montero A. Fiebre chikungunya----Una nueva amenaza global.
Med Clin. 2015;145:118--23.
9. Dirección General de, Epidemiología. Anuarios de morbili-
dad nacional 1984-2014. Morbilidad nacional; 2015 (accessed
Oct 10) Available at: http://www.epidemiologia.salud.gob.mx/
anuario/html/morbilidad nacional.html
0. Dirección General de, Epidemiología. Boletín epidemiológico
semanal; 2015 (accessed Dec 15) Available at: http://www.
epidemiologia.salud.gob.mx/dgae/boletin/intd boletin.html
1. Sivan A, Shriram AN, Sugunan AP, Anwash M, Muruganan-
dam N, Kartik C, et al. Natural transmission of dengue virus
serotype 3 by Aedes albopictus (Skuse) during an outbreak
in Havelock Island: entomological characteristics. Acta Trop.
2016;156:122--9.
2. Chang LJ, Dowd KA, Mendoza FH, Saunders JG, Sitar S,
Plummer SH, et al. Safety and tolerability of chikungunya
virus-like particle vaccine in healthy adults: a phase 1 dose-
escalation trial. Lancet. 2014;384:2046--52, http://dx.doi.org/
10.1016/S0140-6736(14)61185-5
3. Chirathaworn C, Poovorawan Y, Lertmaharit S, Wuttirat-
tanakowit N. Cytokine levels in patients with chikungunya virus
infection. Asian Pac J Trop Med. 2013;6:631--4.
4. Pérez-Sánchez G, Ramírez-Alvarez G, Pérez-Gijón Y, Canela-
Lluch C. Fiebre de Chikungunya: enfermedad infrecuente como
emergencia médica en Cuba. Medisan. 2014;18:859--67.
5. Centers of Disease Control and Prevention; Organización
Panamericana de la Salud. Preparación y respuesta ante la
eventual introducción del virus chikungunya en las Améri-
cas. Available at: http://www1.paho.org/hq/dmdocuments/
CHIKV Spanish.pdf
6. Rivera-Ávila RC. Fiebre chikungunya en México: caso conﬁrmado
y apuntes para su vigilancia epidemiológica. Salud Publica Mex.
2014;56:402--4.
7. Sudeep AB, Parashar D. Chikungunya: an overview. J Biosci.
2008;33:443--9.
8. Suhrbier A, Jaffar-Bandjee MC, Gasque P. Arthritogenic alpha
viruses----an overview. Nat Rev Rheumatol. 2012;8:420--9.
9. Sebastian MR, Lodha R, Kabra SK. Chikungunya Infection in chil-
dren. Indian J Pediatr. 2009;76:185--9.
0. Weaver SC. Arrival of chikungunya virus in the New World:
prospects for spread and impact on public health. PLoS Negl
Trop Dis. 2014;8:e2921.
1. Schwartz O, Albert ML. Biology and pathogenesis of chikungunya
virus. Nat Rev Microbiol. 2010;8:491--500.
2. Weaver SC, Lecuit M. Chikungunya virus and the global spread
of a mosquito-borne disease. N Engl J Med. 2015;372:1231--9.
3. American Academy of Pediatrics. Arboviruses. In: Kimberlin DW,
Brady MT, Jackson MA, Long SS, editors. Red Book: 2015 Report
of the committee on infecctious diseases. Illinois: American
Academy of Pediatrics; 2015. p. 40--6.
4. Pan American Health Organization/Organización Mundial de la
Salud. Número de casos reportados de chikungunya en países
o territorios de las Américas; 2015 (per weeks). Available at:
http://www.paho.org/hq/?Itemid=40931
5. Dirección General de Epidemiología. Aviso epidemiológico
CONAVE/04/2015/Virus Zika, síndrome neurológico y
anomalías congénitas; 2016 (accessed Jan 26) Available at:
72
2
2
2
3
of  a recombinant measles-virus-based chikungunya vac-4  
http://www.epidemiologia.salud.gob.mx/doctos/avisos/2015/
zika/Aviso ZIKA SX NEUROLOGICO 101215.pdf
6.  Panamerican Health Organization, World Health Organization.
Epidemiological update: Neurological syndrome, congeni-
tal anomalies and Zika virus infection. Washington, D.C:
PAHO/WHO;  2016. Available at: http://www.paho.org/hq/
index.php?option=com docman&task=doc view&Itemid=270&
gid=32879&lang=en
7.  Fauci AS, Morens DM. Zika virus in the Americas----yet another
arbovirus threat. N Engl J Med. 2016;374:601--4.
8.  Organización Panamericana de la Salud, Organización Mundial
de la Salud. Información para proveedores de asistencia sani-
taria. Fiebre chikungunya; 2015 (accessed, Oct 16). AvailableM.  Nava-Frías  et  al.
at: http://www.paho.org/hq/index.php?option=com docman&
task=doc details&gid=23977&Itemid=270&lang=es
9. Sinh Nam V, Thi Yen N, Minh Duc H, Cong Tu T, Trong Thang V,
Hoang Le N, et al. Community-based control of Aedes aegypti
by using Mesocyclops in southern Vietnam. Am J Trop Med Hyg.
2012;86:850--9.
0. Ramsauer K, Schwameis M, Firbas C, Müllner M, Putnak RJ,
Thomas SJ, et al. Immunogenicity, safety, and tolerabilitycine: a randomized, double-blind, placebo-controlled, active-
comparator, ﬁrst-in-the-man trial. Lancet Infect Dis. 2015;15:
519--27.
